151 related articles for article (PubMed ID: 34467996)
1. Dysbetalipoproteinemia: Differentiating Multifactorial Remnant Cholesterol Disease From Genetic ApoE Deficiency.
Paquette M; Bernard S; Paré G; Baass A
J Clin Endocrinol Metab; 2022 Jan; 107(2):538-548. PubMed ID: 34467996
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis of remnant hyperlipidaemia.
Paquette M; Bernard S; Baass A
Curr Opin Lipidol; 2022 Aug; 33(4):227-230. PubMed ID: 35942808
[TBL] [Abstract][Full Text] [Related]
3. A simplified diagnosis algorithm for dysbetalipoproteinemia.
Paquette M; Bernard S; Blank D; Paré G; Baass A
J Clin Lipidol; 2020; 14(4):431-437. PubMed ID: 32631794
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis of Familial Dysbetalipoproteinemia Based on the Lipid Abnormalities Driven by APOE2/E2 Genotype.
Bea AM; Cenarro A; Marco-Bened V; Laclaustra M; Martn C; Ibarretxe D; Pint X; Arrobas T; Vials C; Civeira F; Olmos S
Clin Chem; 2023 Feb; 69(2):140-148. PubMed ID: 36644927
[TBL] [Abstract][Full Text] [Related]
5. Non-HDL-cholesterol/apolipoprotein B ratio: a useful distinguishing feature in the screening for type III hyperlipoproteinemia.
Murase T; Okubo M; Takeuchi I
J Clin Lipidol; 2010; 4(2):99-104. PubMed ID: 21122636
[TBL] [Abstract][Full Text] [Related]
6. Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2(Arg158-->Cys), E3-Leiden, and E2(Lys146-->Gln), and effects of treatment with simvastatin.
Zhao SP; Smelt AH; Van den Maagdenberg AM; Van Tol A; Vroom TF; Gevers Leuven JA; Frants RR; Havekes LM; Van der Laarse A; Van 't Hooft FM
Arterioscler Thromb; 1994 Nov; 14(11):1705-16. PubMed ID: 7947593
[TBL] [Abstract][Full Text] [Related]
7. Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2.
Breslow JL; Zannis VI; SanGiacomo TR; Third JL; Tracy T; Glueck CJ
J Lipid Res; 1982 Nov; 23(8):1224-35. PubMed ID: 7175379
[TBL] [Abstract][Full Text] [Related]
8. Triglycerides, hypertension, and smoking predict cardiovascular disease in dysbetalipoproteinemia.
Paquette M; Bernard S; Paré G; Baass A
J Clin Lipidol; 2020; 14(1):46-52. PubMed ID: 31959563
[TBL] [Abstract][Full Text] [Related]
9. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2.
Huang Y; Rall SC; Mahley RW
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2817-24. PubMed ID: 9409260
[TBL] [Abstract][Full Text] [Related]
10. Dysbetalipoproteinemia Is Associated With Increased Risk of Coronary and Peripheral Vascular Disease.
Paquette M; Bernard S; Baass A
J Clin Endocrinol Metab; 2022 Dec; 108(1):184-190. PubMed ID: 36056815
[TBL] [Abstract][Full Text] [Related]
11. Severe Combined Dyslipidemia With a Complex Genetic Basis.
Le R; Abbas M; McIntyre AD; Hegele RA
J Investig Med High Impact Case Rep; 2019; 7():2324709619877050. PubMed ID: 31538826
[No Abstract] [Full Text] [Related]
12. Hyperlipidemic myeloma, a rare form of acquired dysbetalipoproteinemia, in an HIV seropositive African female.
Seedat F; Patel M; Phillip V; Mohamed F; Marais AD; Blackhurst DM; Solomon G; Currin S; Raal FJ
Clin Chim Acta; 2021 Sep; 520():71-75. PubMed ID: 34052205
[TBL] [Abstract][Full Text] [Related]
13. Influence of APOE-2 genotype on the relation between adiposity and plasma lipid levels in patients with vascular disease.
Koopal C; van der Graaf Y; Asselbergs FW; Westerink J; Visseren FL;
Int J Obes (Lond); 2015 Feb; 39(2):265-9. PubMed ID: 24946908
[TBL] [Abstract][Full Text] [Related]
14. Dysbetalipoproteinemia: an extreme disorder of remnant metabolism.
Marais D
Curr Opin Lipidol; 2015 Aug; 26(4):292-7. PubMed ID: 26103610
[TBL] [Abstract][Full Text] [Related]
15. Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in the APOE gene.
Heidemann BE; Koopal C; Baass A; Defesche JC; Zuurbier L; Mulder MT; Roeters van Lennep JE; Riksen NP; Boot C; Marais AD; Visseren FLJ
Clin Genet; 2022 Oct; 102(4):253-261. PubMed ID: 35781703
[TBL] [Abstract][Full Text] [Related]
16. Roles of high apolipoprotein E blood levels and HDL in development of familial dysbetalipoproteinemia in ε2ε2 subjects.
Corsetti JP; Sparks CE; Bakker SJL; Gruppen EG; Dullaart RPF
Clin Biochem; 2018 Feb; 52():67-72. PubMed ID: 29157655
[TBL] [Abstract][Full Text] [Related]
17. Triglyceride-rich lipoproteins of subjects heterozygous for apolipoprotein E2(Lys146-->Gln) are inefficiently converted to cholesterol-rich lipoproteins.
Mulder M; van der Boom H; de Knijff P; Braam C; van den Maagdenberg A; Leuven JA; Havekes LM
Atherosclerosis; 1994 Aug; 108(2):183-92. PubMed ID: 7980718
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Non-HDL Cholesterol to Apolipoprotein B Ratio as a Screening Test for Dysbetalipoproteinemia.
Boot CS; Middling E; Allen J; Neely RDG
Clin Chem; 2019 Feb; 65(2):313-320. PubMed ID: 30538126
[TBL] [Abstract][Full Text] [Related]
19. Tuberous xanthomas associated with olanzapine therapy and hypertriglyceridemia in the setting of a rare apolipoprotein E mutation.
Sinnott BP; Mazzone T
Endocr Pract; 2006; 12(2):183-7. PubMed ID: 16690468
[TBL] [Abstract][Full Text] [Related]
20. Familial dysbetalipoproteinemia: a genetically heterogenous disease caused by mutations of the ligand apolipoprotein E.
Vermeer BJ; Frants RR; Havekes LM
J Invest Dermatol; 1992 Jun; 98(6 Suppl):57S-60S. PubMed ID: 1588125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
